The $1.9 Billion Bet: Chiesi Acquires KalVista, Redefining Rare Disease Value

Related Articles

Amicus Therapeutics: A Rare Disease Gem Acquired

8 months ago

What Does FDA Orphan Drug Designation Mean for Cure Rare Disease's SCA3 Treatment

7 months ago

Is the Satellite-to-Cell Race Redefining Telecom Connectivity

7 months ago

How is AI Redefining Customer Service and What Does it Mean for Businesses

7 months ago

Category

You may also like

Stock News•1 months ago

BioCryst Eyes $1B Rare-Disease Future Through External Innovation

BioCryst Pharmaceuticals is shifting toward external innovation to expand beyond its ORLADEYO HAE franchise, newly appointed CEO Charlie Gayer said at a Morgan Stanley event, targeting a $1B rare-dise...

BCRX

Share

Stock News•1 months ago

Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case

Dianthus Therapeutics holds ~$1.2B in cash, supporting late-stage programs through 2030. Claseprubart's differentiated profile strengthens its bull case after Sanofi's setback, reducing funding risk a...

DNTH

Share

Stock News•3 months ago

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Big Pharma is spending at a pace not seen since 2019 to replace ~$300B in drugs losing patent protection, fueling biotech acquisitions.

ABBV

Share